Advances and Challenges in Immunotherapy for Metastatic Uveal Melanoma: Clinical Strategies and Emerging Targets is a research paper published in Journal of Clinical Medicine (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →School of Pharmacy at the University of Texas at El Paso
Grant: 14648680
School of Pharmacy at the University of Texas at El Paso
Grant: W81XWH-19-1-0282
School of Pharmacy at the University of Texas at El Paso
Grant: R16GM145559
The University of Texas at El Paso
Grant: University Research Institute (URI) Award (14648680),
NIH HHS
Grant: 1R16GM145559-22
The Lizanell and Colbert Coldwell Foundation
Grant: Research Grant
The University of Texas at El Paso
Grant: Startup fund of the School of Pharmacy
National Institutes of Health
Grant: 5R16GM145559-02
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
FWCI
2.06
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals